Welcome to our dedicated page for Immunocore Holdings plc American Depositary Shares news (Ticker: $IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunocore Holdings plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunocore Holdings plc American Depositary Shares's position in the market.
Immunocore reported first quarter financial results with KIMMTRAK® net revenues of $70.3 million in Q1 2024. The company continues to expand global access with 7 additional launches since January 2024. Phase 1/2 brenetafusp clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024. Financially, the company saw a 36% increase in net product revenue, with total revenue reaching $70.3 million in Q1 2024. However, research & development expenses also grew, resulting in a net loss for the quarter. Cash and cash equivalents stood at $832.8 million as of March 31, 2024.